Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Completed · Phase 3 · Has a placebo group

Conditions studied: Depressive Disorder, Major

In brief

The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.

Key facts

Study ID

NCT00384033

Run by

Pfizer

People needed

638

Starts

2006-09-01

Expected to finish

2007-09-01

Last updated by the study team

2012-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A primary diagnosis of Major Depressive Disorder, single or recurrent episode, without psychotic features.
• Depressive symptoms for at least 30 days before the screening visit.
• Outpatient men and women at least 18 years of age.

You may not qualify if…

• Significant risk of suicide based on clinical judgment, including common suicidal thoughts and suicide having been considered as a possible solution even without specific plans or intent.
• Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled hypertension), ophthalmologic, neurologic, or any other medical condition that might confound the study or put the subject at greater risk during study participation.
• Current (within 12 months before baseline) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder; b) current (within 12 months before baseline) generalized anxiety disorder, panic disorder, or social anxiety disorder; c) presence (within 12 months before baseline) of a clinically important personality disorder as assessed during the psychiatric assessments.

Where it is running

• Pfizer Investigational Site — Beverly Hills, California, United States
• Pfizer Investigational Site — Burbank, California, United States
• Pfizer Investigational Site — Encino, California, United States
• Pfizer Investigational Site — Los Alamitos, California, United States
• Pfizer Investigational Site — Newport Beach, California, United States
• Pfizer Investigational Site — Northridge, California, United States
• Pfizer Investigational Site — Orange, California, United States
• Pfizer Investigational Site — Pasadena, California, United States
• Pfizer Investigational Site — Upland, California, United States
• Pfizer Investigational Site — South Miami, Florida, United States
• Pfizer Investigational Site — St. Petersburg, Florida, United States
• Pfizer Investigational Site — Edwardsville, Illinois, United States
• Pfizer Investigational Site — Farmington Hills, Michigan, United States
• Pfizer Investigational Site — Flint, Michigan, United States
• Pfizer Investigational Site — Okemos, Michigan, United States
• Pfizer Investigational Site — Clementon, New Jersey, United States
• Pfizer Investigational Site — Dayton, Ohio, United States
• Pfizer Investigational Site — Portland, Oregon, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Salt Lake City, Utah, United States
• Pfizer Investigational Site — Seattle, Washington, United States
• Pfizer Investigational Site — Brown Deer, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.